Indian Medtech Breakthrough: Meril Life Sciences Shines At PCR London Valves 2025

Updated: November 30, 2025 08:25

Image Source : Business Standard

Meril Life Sciences, an Indian MedTech company, made global headlines at PCR London Valves 2025 by presenting one-year outcomes from its LANDMARK Randomized Controlled Trial. The trial compared its indigenous Myval transcatheter heart valve (THV) series against global giants Edwards Lifesciences and Medtronic, showcasing India’s growing credibility in cardiovascular innovation.

India’s MedTech sector achieved a milestone moment at PCR London Valves 2025, one of the world’s most prestigious conferences on structural heart interventions. Meril Life Sciences presented pivotal one-year results from the LANDMARK Randomized Controlled Trial (RCT), the first-ever multicenter RCT to evaluate an Indian-developed THV against leading international platforms.

The Myval THV series, a balloon-expandable transcatheter heart valve developed indigenously, demonstrated comparable efficacy to established global systems. This achievement underscores India’s rising influence in cardiovascular innovation and highlights the country’s ability to deliver world-class medical technology solutions.

Key highlights from the announcement include

Meril Life Sciences presented one-year outcomes of the LANDMARK RCT at PCR London Valves 2025.
The trial compared India’s Myval THV series with Edwards Lifesciences and Medtronic platforms.
It is the first multicenter RCT evaluating an Indian-developed THV against global leaders.
Myval THV demonstrated comparable composite clinical efficacy, including freedom from all-cause mortality and major adverse events.
The results enhance India’s credibility in global cardiovascular device innovation.
Meril’s achievement reflects the growing strength of India’s MedTech ecosystem.
The presentation was part of the Late-Breaking Trial sessions, highlighting its global significance.
The development positions India as a reliable contributor to structural heart solutions worldwide.
The trial outcomes are expected to boost confidence among clinicians and regulators in adopting Indian-developed THVs.
Meril Life Sciences continues to expand its footprint in advanced cardiovascular technologies.

This breakthrough not only elevates Meril Life Sciences but also signals India’s emergence as a serious player in the global MedTech arena. By competing head-to-head with established international giants, India’s innovation story is gaining recognition, paving the way for greater adoption of indigenous medical technologies worldwide.

Sources: Business Standard, ANI News, Devdiscourse

Stay Ahead – Explore Now! Game Changer in Indian Logistics: IndoSpace’s INR 30 Billion Industrial Parks Acquisition Sets New Benchmark